Seres Therapeutics, Inc. Logo

Seres Therapeutics, Inc.

Developing live biotherapeutics from the microbiome to treat infections and immune diseases.

MCRB | US

Overview

Corporate Details

ISIN(s):
US81750R2013
LEI:
Country:
United States of America
Address:
200 SIDNEY STREET, 2139 CAMBRIDGE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Seres Therapeutics, Inc. is a commercial-stage biotechnology company pioneering the development of live biotherapeutics. The company focuses on modulating the gastrointestinal microbiome to treat serious diseases. Its platform creates rationally designed consortia of live bacteria intended to transform the lives of medically vulnerable patients. Seres Therapeutics' programs target the prevention of bacterial bloodstream and antimicrobial-resistant (AMR) infections, as well as the treatment of gastrointestinal-related immune diseases such as inflammatory bowel disease.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Seres Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Seres Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Seres Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Equillium, Inc. Logo
Clinical-stage biotech creating therapies for severe autoimmune and inflammatory disorders.
United States of America EQ
Erasca, Inc. Logo
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America ERAS
Ernexa Therapeutics Inc. Logo
Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.
United States of America ERNA
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France ERYP
Esperion Therapeutics, Inc. Logo
Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.
United States of America ESPR
ESSA Pharma Inc. Logo
Develops novel small molecule drugs to treat castration-resistant prostate cancer.
United States of America EPIX
Estrella Immunopharma, Inc. Logo
Clinical-stage biopharma developing ARTEMIS® T-cell therapies for cancer & autoimmune disease.
United States of America ESLA
Eton Pharmaceuticals, Inc. Logo
Develops and commercializes innovative treatments for rare pediatric diseases.
United States of America ETON
EuBiologics Co., Ltd. Logo
Develops vaccines for global public health and provides biopharmaceutical CRMO services.
South Korea 206650
EUPRAXIA PHARMACEUTICALS INC. Logo
Developing targeted, extended-release therapies for GI and musculoskeletal diseases.
United States of America EPRX

Talk to a Data Expert

Have a question? We'll get back to you promptly.